James C Gilbert Selected Research

ARC 1779

8/2012	The anti-von Willebrand factor aptamer ARC1779 increases von Willebrand factor levels and platelet counts in patients with type 2B von Willebrand disease.
4/2012	Initial experience from a double-blind, placebo-controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura.
11/2011	An anti-von Willebrand factor aptamer reduces platelet adhesion among patients receiving aspirin and clopidogrel in an ex vivo shear-induced arterial thrombosis.
9/2011	A dose ranging phase I/II trial of the von Willebrand factor inhibiting aptamer ARC1779 in patients with congenital thrombotic thrombocytopenic purpura.
3/2011	Inhibition of von Willebrand factor by ARC1779 in patients with acute thrombotic thrombocytopenic purpura.
9/2010	A randomised pilot trial of the anti-von Willebrand factor aptamer ARC1779 in patients with type 2b von Willebrand disease.
5/2010	The aptamer ARC1779 blocks von Willebrand factor-dependent platelet function in patients with thrombotic thrombocytopenic purpura ex vivo.
10/2009	Anti-von Willebrand factor aptamer ARC1779 for refractory thrombotic thrombocytopenic purpura.
8/2009	The aptamer ARC1779 is a potent and specific inhibitor of von Willebrand Factor mediated ex vivo platelet function in acute myocardial infarction.
12/2007	First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

James C Gilbert Research Topics

Disease

6	Thrombotic Thrombocytopenic Purpura 04/2012 - 10/2009
4	Thrombosis (Thrombus) 01/2020 - 11/2011
3	Type 2 von Willebrand Disease 01/2022 - 09/2010
3	Stroke (Strokes) 01/2021 - 01/2018
3	Hemorrhage 09/2011 - 12/2007
2	Hemolysis 01/2020 - 01/2019
2	Autoimmune Hemolytic Anemia (Cold Agglutinin Disease) 01/2020 - 01/2019
2	Myocardial Infarction 01/2020 - 08/2009
2	Thrombocytopenia (Thrombopenia) 08/2012 - 09/2010
2	Acute Coronary Syndrome 03/2008 - 12/2007
1	Vascular System Injuries 01/2020
1	Heart Failure 12/2019
1	Bullous Pemphigoid (Pemphigoid) 12/2019
1	Hemolytic Anemia 01/2019
1	Ischemic Stroke 01/2018
1	Atherosclerosis 01/2018
1	Hemophilia A (Haemophilia) 01/2014
1	Coronary Artery Disease (Coronary Atherosclerosis) 11/2011
1	Neurologic Manifestations (Neurological Manifestations) 01/2011
1	Critical Illness (Critically Ill) 10/2009
1	Cardiovascular Diseases (Cardiovascular Disease) 03/2008
1	Atherosclerotic Plaque (Atheroma) 03/2008
1	Splenic Rupture 12/2004
1	Appendicitis 10/2004
1	Rupture 10/2004

Drug/Important Bio-Agent (IBA)

15	von Willebrand FactorIBA 01/2022 - 03/2008
10	ARC 1779IBA 08/2012 - 12/2007
5	thiamine triphosphorate (TTP)IBA 09/2011 - 10/2009
3	Platelet Membrane GlycoproteinsIBA 01/2022 - 01/2020
3	sutimlimabIBA 01/2020 - 01/2019
3	Pharmaceutical PreparationsIBA 12/2019 - 01/2014
2	Complement C1s (C1 Esterase)IBA 01/2020 - 01/2019
2	Hemoglobins (Hemoglobin)IBA 01/2020 - 01/2019
2	Complement System Proteins (Complement)IBA 12/2019 - 01/2019
2	FibrinIBA 01/2014 - 05/2010
2	Deamino Arginine Vasopressin (Desmopressin)FDA LinkGeneric 08/2012 - 09/2010
1	Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA 01/2020
1	Proteins (Proteins, Gene)FDA Link 01/2020
1	CollagenIBA 01/2020
1	TNT009IBA 12/2019
1	AutoantibodiesIBA 12/2019
1	Immunoglobulin M (IgM)IBA 01/2019
1	AntibodiesIBA 01/2019
1	HaptoglobinsIBA 01/2019
1	BilirubinIBA 01/2019
1	EnzymesIBA 01/2018
1	Factor VIII (Coagulation Factor VIII)IBA 01/2014
1	ARC19499IBA 01/2014
1	lipoprotein-associated coagulation inhibitor (TFPI)IBA 01/2014
1	Clopidogrel (Plavix)FDA Link 11/2011
1	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 11/2011
1	Platelet Glycoprotein GPIb-IX Complex (Glycoprotein Ib)IBA 05/2010
1	Fibrinolytic Agents (Antithrombotic Agents)IBA 12/2007

Therapy/Procedure

3	Therapeutics 12/2019 - 10/2009
2	Secondary Prevention 01/2020 - 01/2018
1	Plasma Exchange 10/2009
1	Splenectomy 12/2004
1	Appendectomy 10/2004